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Abstract
Lafora disease (LD) is a fatal progressive epilepsy essentially caused
by loss-of-function mutations in the glycogen phosphatase laforin
or the ubiquitin E3 ligase malin. Glycogen in LD is hyperphosphory-
lated and poorly hydrosoluble. It precipitates and accumulates into
neurotoxic Lafora bodies (LBs). The leading LD hypothesis that
hyperphosphorylation causes the insolubility was recently chal-
lenged by the observation that phosphatase-inactive laforin
rescues the laforin-deficient LD mouse model, apparently through
correction of a general autophagy impairment. We were for the
first time able to quantify brain glycogen phosphate. We also
measured glycogen content and chain lengths, LBs, and autophagy
markers in several laforin- or malin-deficient mouse lines express-
ing phosphatase-inactive laforin. We find that: (i) in laforin-
deficient mice, phosphatase-inactive laforin corrects glycogen
chain lengths, and not hyperphosphorylation, which leads to
correction of glycogen amounts and prevention of LBs; (ii) in
malin-deficient mice, phosphatase-inactive laforin confers no
correction; (iii) general impairment of autophagy is not necessary
in LD. We conclude that laforin’s principle function is to control
glycogen chain lengths, in a malin-dependent fashion, and that
loss of this control underlies LD.
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Introduction
Lafora disease (LD) is a recessively inherited teenage-onset severe
and fatal progressive myoclonus epilepsy. Its etiopathological hall-
mark is the Lafora body (LB), present throughout the brain in
profuse ever-increasing numbers and sizes (Lafora & Glueck, 1911;
Minassian, 2001). LBs are overwhelmingly composed of an abnor-
mally formed glycogen (Sakai et al, 1970) and likely result from
gradual precipitation, aggregation and accumulation of abnormal
glycogen.
Normally glycogen consists of highly and regularly branched
roughly sphere-shaped molecules, each composed of up to 55,000
glucose units. It is mainly synthesized by coordinated actions of
glycogen synthase (GS), which elongates glucan chains forming a1-4
interglucosidic linkages, and glycogen branching enzyme, which
detaches a part of each newly formed chain and reattaches it to
another glucan chain through an a1-6 linkage. Glycogen is essen-
tially degraded by glycogen phosphorylase and glycogen debranch-
ing enzyme. Glucan chains of glycogen have a wide chain length
distribution with an average of ~13 units (Roach et al, 2012;
Nitschke et al, 2013). High frequency of branching points and rela-
tively short chains are critical for glycogen solubility. They prevent
neighbouring chains from forming double helices, which otherwise
exclude water, reduce the water solubility of the interacting chains
and finally lead the entire molecule to precipitate. Incidentally, the
main component of plant starch amylopectin is insoluble precisely
because it is composed of longer chains that through clustered
arrangement of branch points form crystalline areas of double
helices (Roach et al, 2012; Cenci et al, 2014). Glycogen and amylo-
pectin possess phosphate esters bound to a very small number of
glucose units, in glycogen’s case at carbon positions C2, C3 and C6
(Tagliabracci et al, 2011; Nitschke et al, 2013). The kinase(s)
responsible for glycogen phosphorylation are not known, except that
GS itself has been reported to be involved in C3 phosphorylation
through what so far has been considered an undesirable side reac-
tion of the enzyme (Tagliabracci et al, 2011; Contreras et al, 2016).
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The abnormal glycogen constituting LBs has three characteris-
tics: (i) its chain length distribution contains longer chains than
normal glycogen, (ii) its phosphate levels are elevated, and (iii)
its quantity is high, the latter reflecting the profuse deposition as
LBs (Tagliabracci et al, 2008; Nitschke et al, 2013). LD is mainly
caused by loss-of-function mutations in either the EPM2A (laforin)
or EPM2B (malin) gene, and knockout of either in mouse recapit-
ulates the disease (Minassian et al, 1998; Ganesh et al, 2002;
Chan et al, 2003; Turnbull et al, 2010). Laforin is a glycogen
phosphatase, its absence resulting in progressive glycogen hyper-
phosphorylation (Worby et al, 2006; Tagliabracci et al, 2008).
Malin is a ubiquitin E3 ligase (Gentry et al, 2005), which in cell
culture experiments, in a laforin-dependent fashion, diminishes
both GS and a protein involved in GS activation, R5/PTG, through
proteasomal degradation (Vilchez et al, 2007; Worby et al, 2008).
Malin, again in a laforin-dependent manner, also diminishes a
second protein that participates in GS activation, R6, in this case
through autophagic degradation (Rubio-Villena et al, 2013).
Laforin and malin form a functional complex, the former (but not
the latter) possessing a carbohydrate binding domain through
which the complex is targeted to glycogen (Gentry et al, 2005;
Lohi et al, 2005).
From the above results, two main hypotheses were advanced
to explain the abnormal glycogen formation in LD: (i) absence of
laforin or malin leads to increased GS activity, which outpacing
branching leads to the formation of glycogen with long chains
promoting water insolubility (Vilchez et al, 2007); and (ii) laforin
deficiency results in non-removal of erratically introduced phos-
phate and thus hyperphosphorylation of glycogen, which via an
unknown mechanism alters its structure promoting glycogen
precipitation (Tagliabracci et al, 2008; Roach, 2015). Both
hypotheses, however, were challenged by more recent findings. (i)
Tissues from laforin and malin knockout mice were shown to
have unaltered GS activity (Tagliabracci et al, 2008; DePaoli-Roach
et al, 2010). (ii) When phosphatase-inactive laforin was overex-
pressed in laforin knockout mice, LBs no longer formed and the
mice were rescued from LD (Gayarre et al, 2014). The latter result
was particularly provocative. It suggested that laforin’s chief and
only established physiological function (glycogen dephosphoryla-
tion) and the major and distinguishing pathological feature of LD
glycogen (progressive hyperphosphorylation) were irrelevant to LB
formation and LD.
Gayarre et al, however, left a number of critical questions unad-
dressed before the field could make a decided paradigm shift away
from the centrality of glycogen phosphate in LB formation and LD
towards exploring alternative disease mechanisms. They did not
measure glycogen phosphate. It can, therefore, not be excluded that
the overexpressed in vitro-inactive laforin had retained some phos-
phatase activity in vivo or that there was a small amount of wild-
type (WT) laforin somehow still expressed in the transgenic mice.
Laforin’s phosphatase activity is catalysed by a cysteine residue
(C265 in mouse, C266 in human), which Gayarre and colleagues
had mutated to serine to inactivate the enzyme. Recently, crystal
structures of laforin were determined (Raththagala et al, 2015;
Sankhala et al, 2015) suggesting the presence of a putative second
phosphatase site in laforin (C168 in mouse, C169 in human). The
C168 site could be active in vivo, especially when overexpressed,
and explain the rescue by laforin mutated only at C265.
The other two features specific to LD glycogen, chain length
distribution and quantity, were also outside the scope of the above
study and had not been analysed. As such, conclusions about the
mechanism conferring rescue from LBs remained tentative. It was
possible, for example, that the rescued mice did accumulate abnor-
mal glycogen, which, coated with a large amount of hydrophilic
protein (overexpressed laforin), remained soluble and did not
coalesce into pathologically observable LBs.
In this work, we address all these points by characterizing
glycogen in both laforin- and malin-deficient mice as affected by
overexpressed WT and phosphatase-inactive laforin. Our results
combine with previous studies to allow the proposal of a unifying
hypothesis of LB pathogenesis in both laforin- and malin-deficient
LD.
Results
Amounts and molecular parameters of muscle glycogen in
Epm2a/ mice overexpressing phosphatase-inactive laforin
We quantified total glycogen from skeletal muscle from the actual
mice used in the Gayarre et al study (Gayarre et al, 2014). In
Epm2a/ mice, muscle glycogen content was fivefold increased, as
in previous studies (Tagliabracci et al, 2008). In Epm2a/ mice
overexpressing WT laforin (Epm2a/.Laf), muscle glycogen
content was normal. In Epm2a/ mice overexpressing phos-
phatase-inactive laforin (Epm2a/.C265SLaf), muscle glycogen
content was also normal (Fig 1A), indicating that the prevention of
LBs (which are aggregates of insoluble glycogen) by phosphatase-
inactive laforin (Gayarre et al, 2014) is indeed due to the prevention
of generating insoluble glycogen, as opposed to merely maintaining
the excess abnormal glycogen in a soluble state.
We measured total glycogen phosphate in the above tissues,
which in Epm2a/ mice was 14-fold increased, as in previous stud-
ies (Tagliabracci et al, 2008). Levels were normal in Epm2a/.Laf
mice, but in Epm2a/.C265SLaf mice glycogen phosphate was
just as high as in Epm2a/ mice (Fig 1B). This indicates that
phosphatase-inactive laforin indeed has no phosphatase activity
in vivo and does not normalize the hyperphosphorylation
characteristic of LD glycogen. This in turn indicates that glycogen
hyperphosphorylation does not cause the generation of insoluble
glycogen.
Measurement of total glycogen phosphate requires relatively
large amounts of purified glycogen (see Materials and Methods). Of
the three glucosyl carbons phosphorylated in glycogen, C6 phospho-
rylation is the only one for which a sensitive method has been
developed that allows site-specific quantification. Moreover, C6
phosphate can be measured in very small amounts of glycogen, and
as all three phosphorylation sites are proportionally high in LD
(DePaoli-Roach et al, 2015; Roach, 2015), it can be used as a
measure of total glycogen phosphorylation. While sufficient
amounts of glycogen can be purified from skeletal muscle for total
glycogen phosphate measurement, this is currently unfeasible for
brain glycogen, where C6 phosphorylation only would be quantified
as an indicator of the total. Leading up to the brain studies (next
sections), we measured C6 glycogen phosphate in skeletal muscle
and found that it is, as expected, like total glycogen phosphate,
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increased in both the Epm2a/ and Epm2a/.C265SLaf mice
(Fig 1C).
Besides glycogen amount and phosphate content, the third
feature that distinguishes LD from WT glycogen is chain length
distribution. We measured skeletal muscle glycogen chain lengths
in the above genotypes and found that the chain length distribution
in Epm2a/ mice is abnormal with a significantly increased
proportion of longer chains, while in Epm2a/.C265SLaf mice (and
of course Epm2a/.Laf mice) the chain length distribution is
normal, indicating that phosphatase-inactive laforin rescues the
glycogen chain length abnormality characteristic of LD glycogen
(Fig 1D).
To summarize, phosphatase-inactive laforin does not correct the
hyperphosphorylation of LD muscle glycogen, but does normalize
the glycogen’s chain length distribution preventing abnormal glyco-
gen accumulation and LB formation.
Brain glycogen in Epm2a/ and Epm2b/ mouse lines
overexpressing phosphatase-inactive laforin
Generation of new mouse line
The implications of the Gayarre et al (2014) study and our above
results are major: Laforin’s phosphatase function is dispensable and
glycogen hyperphosphorylation is not pathogenic. These results run
counter to a leading LD hypothesis, in which glycogen phosphoryla-
tion is considered a damaging side product of GS activity that needs
to be cleared by laforin (Tagliabracci et al, 2011; Raththagala et al,
2015; Roach, 2015; Contreras et al, 2016; Turnbull et al, 2016). To
rule out the possibility of an artefact in the Gayarre et al mice, we
generated a whole new set of Epm2a/, and this time also
Epm2b/ mice overexpressing phosphatase-inactive laforin. Phos-
phatase-inactive human laforin (C266SLaf) was used, in contrast to
the phosphatase-inactive murine laforin (C265SLaf) used by Gayarre
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Figure 1. Phosphatase-inactive laforin does not correct LD muscle glycogen hyperphosphorylation, but does correct its chain length distribution and
prevents abnormal glycogen accumulation.
Laf indicates WT laforin and C265Laf indicates phosphatase-inactive laforin transgenes, respectively, expressed in indicated LD mouse model (Epm2a/).
A Glycogen content.
B Glycogen total phosphate content.
C Glycogen carbon C6 phosphate content.
D Chain length distribution analyses.
Data information: Means of > 5 biological replicates are presented as bars in (A–C) or as circles in (D). Standard deviations are presented as error bars in (A–C), or as blue
(WT), red (Epm2a/) or grey shades (Epm2a/.Laf and Epm2a/.C265SLaf) in (D). Asterisks, statistical significance by ANOVA and post hoc analyses (*P < 0.05,
**P < 0.01, ***P < 0.001; Appendix Table S1).
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et al (2014). We did so by crossing WT mice overexpressing
C266SLaf available in our laboratory (Chan et al, 2004) with
Epm2a/ (Ganesh et al, 2002) and Epm2b/ (Turnbull et al,
2010) mice. The resultant transgenic animals are termed Epm2a/.
C266SLaf and Epm2b/.C266SLaf, respectively.
We simultaneously analysed glycogen and LBs from this new
line and from the Gayarre et al Epm2a/.C265SLaf mice, focusing
on brain, the disease-relevant organ. Consistency of findings in
Gayarre et al and our mice would confirm phosphatase-inactive
laforin’s effect on glycogen and obviate results arising from any
particularities of each mouse line studied. The differences between
the mouse lines are transgene species (as mentioned above), pres-
ence or absence of a tag on the transgene protein, expression level,
and mouse background (Chan et al, 2004; Gayarre et al, 2014). We
had previously generated the C266SLaf mice (Chan et al, 2004) in
an attempt to create an LD mouse model through a dominant-nega-
tive approach. The phosphatase-inactive laforin (C266SLaf) was
supposed to outcompete WT laforin’s phosphatase activity and lead
to an effective loss of the endogenous laforin function. In fact, the
resultant mice did have a few LBs and we reported this mouse as a
mild, only-pathological, model of LD, with no neurological pheno-
type (Chan et al, 2004). Compared to the laforin (and malin) knock-
out mice (Epm2a/ and Epm2b/, respectively) (Ganesh et al,
2002; Turnbull et al, 2010), the number of LBs occurring in this
model is orders of magnitude lower (Fig 2), and negligible for
purposes of the present experiments.
Glycogen and LB analyses
Brain glycogen content was threefold to fourfold increased in both
Epm2a/ mouse lines and in Epm2b/ mice, as previously
published (Tagliabracci et al, 2008; DePaoli-Roach et al, 2010;
Turnbull et al, 2010). Brain glycogen content was normal in
Epm2a/.C265SLaf and Epm2a/.C266SLaf mice, but remained
elevated in Epm2b/.C266SLaf mice (Fig 3A and B). Thus, overex-
pressed phosphatase-inactive laforin corrects the abnormal glycogen
accumulation in laforin-deficient LD but not in malin-deficient LD.
The latter indicates that the rescue in the former is not through
some mechanism related to overexpressed protein (somehow physi-
cally solubilizing insoluble glycogen) as otherwise the same correc-
tion would be expected in the malin-deficient background.
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Figure 2. Phosphatase-inactive laforin prevents Epm2a/ but not Epm2b/ from LB formation.
Representative PASD-stained sections of hippocampi from WT, Epm2a/ and Epm2b/ mice in the absence or presence of the human C266S mutated laforin transgene
(.C266SLaf). Scale bar equals 100 lm.
Source data are available online for this figure.
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Consistent with the rescue of the abnormal brain glycogen accu-
mulation in the Epm2a/.C265SLaf and Epm2a/.C266SLaf mice,
there were no LBs in the brains of these mice. LBs were, however,
still present in the Epm2b/.C266SLaf mice, and to the same extent
as in their Epm2b/ controls (Fig 2), again indicating that phos-
phatase-inactive laforin prevents LB formation in laforin-deficient
but not malin-deficient LD.
We next measured brain glycogen phosphate (via C6 phosphate
quantification). Due to particularities of brain tissue, this (and the
below glycogen chain length analyses) required extensive new
method development, detailed in the Materials and Methods section,
and the results represent the first time these analyses have been
possible in brain. Brain glycogen phosphate was threefold and
twofold elevated in Epm2a/ and Epm2b/ mice, respectively,
similar to muscle glycogen phosphate (Tagliabracci et al, 2008;
DePaoli-Roach et al, 2010; Turnbull et al, 2010). This increase was
not corrected in any of the three phosphatase-inactive laforin
expressing mouse genotypes (Epm2a/.C265SLaf, Epm2a/.
C266SLaf and Epm2b/.C266SLaf) (Fig 4). Taken together, the
results in this section clearly indicate that hyperphosphorylation of
glycogen is not pathogenic nor is it causative of abnormal glycogen
accumulation and LB formation.
Similar to previous findings in muscle glycogen (Fig 1D; see also
Nitschke et al, 2013), but even more pronounced, brain glycogen
chain length distributions were abnormal, significantly shifted
towards longer chains, in Epm2a/ and Epm2b/ mice. They
were normalized in Epm2a/.C265SLaf and Epm2a/.C266SLaf
mice (indistinguishable from WT) and remained abnormal in
Epm2b/.C266SLaf (Fig 5). This demonstrates that phosphatase-
inactive laforin can correct the brain glycogen chain length abnor-
mality in laforin-deficient LD, but not in malin-deficient LD. These
results tease apart, for the first time, the three characteristics of
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Figure 3. Phosphatase-inactive laforin rescues Epm2a/, but not Epm2b/ abnormal glycogen accumulation in the brain.
A Brain glycogen levels in the presence or absence of WT (.Laf) or C265S mutated (.C265Laf) murine laforin transgene (tissues from the Gayarre et al, 2014 study).
B Brain glycogen levels of WT, Epm2a/ and Epm2b/ mice in the presence or absence of human C266S mutated laforin (.C266SLaf) (tissues from the new mice
generated in the present study).
Data information: Data are presented as means of at least five biological replicates  SEM. Asterisks, statistical significance by ANOVA and post hoc analyses (*P < 0.05,
**P < 0.01, ***P < 0.001; Appendix Table S2).
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abnormal LD glycogen (glycogen accumulation, hyperphosphoryla-
tion, abnormal chain length distribution) and indicate that the altered
glycogen chain length distribution, and not hyperphosphorylation,
correlates with abnormal glycogen accumulation and LB formation.
Moreover, phosphatase-inactive laforin’s ability to rescue the chain
length abnormality (and the abnormal glycogen accumulation/LBs)
depends on the presence of malin, as this correction does not occur in
the malin-deficient mice (Epm2b/.C266SLaf). This implies that
laforin (irrespective of its phosphatase domain) and malin impact
glycogen chain length distribution and prevent LB formation and LD
concertedly. It directly links both proteins to glycogen structure
in vivo and corroborates the close laforin–malin partnership previ-
ously suggested by cell culture overexpression experiments (Gentry
et al, 2005; Lohi et al, 2005; Vilchez et al, 2007).
Effect of phosphatase-inactive laforin on LD-associated general defect
in autophagy
LC3 becomes lipidated (i.e. LC3-I converts to LC3-II) as it joins
proliferating autophagosomes during autophagy, and therefore
decreased LC3-II indicates decreased autophagy. p62 directs ubiqui-
tinated proteins to autophagy, and thus, accumulation of p62
indicates failing autophagy. LD mouse brains were shown to have
reduced LC3-II and increased p62, suggesting that LD mice have
impaired autophagy and that this defect underlies LB accumulation
(Criado et al, 2012). Gayarre and colleagues reported normalization
of LC3-II levels in their Epm2a/.C265Laf mice, suggesting that
phosphatase-inactive laforin rescues laforin knockout mice by
correcting the autophagic defect (Gayarre et al, 2014). We tested
brain LC3-II and p62 in the new mice generated for the present
study and found no differences in either protein between WT,
Epm2a/, Epm2b/, Epm2a/.C266Laf, and Epm2b/.C266Laf
genotypes (Fig 6). These results imply that impaired autophagy may
not be a common feature to all LD models and, therefore, it is not a
strict requirement for LD.
Discussion
The report that phosphatase-inactive laforin rescues laforin-deficient
LD (Gayarre et al, 2014) runs contrary to the widely accepted view
that the disease is caused by lack of laforin-mediated clearance of
erratic glycogen phosphorylation (Raththagala et al, 2015; Roach,
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Figure 5. Phosphatase-inactive laforin rescues brain glycogen chain length distribution in Epm2a/ but not Epm2b/ LD.
Top row from tissues from the Gayarre et al (2014) study; bottom two rows from mice generated in the present work. Chain lengths (x-axes) are given as degrees of
polymerization (DP), that is, numbers of glucose units per chain. Laf indicates WT laforin transgene expressed in indicated LD genotype. C265SLaf and C266SLaf indicate
phosphatase-inactive murine or human laforin, respectively, expressed in indicated LD genotype. Data are presented as means of relative peak areas for each DP with shades
representing standard deviation (SD; blue, WT; red, Epm2a/ or Epm2b/; grey, indicated transgenic mice; n > 5, for Epm2a/.Laf samples were pooled). In all panels
relating to transgenic mice, in addition to the chain length distribution in these mice, SD shades of WT or respective knockout mutants (Epm2a/ or Epm2b/) are shown to
allow direct comparisons of the chain length distribution curves. Asterisks, statistical significance by ANOVA and post hoc analyses with regard to DP abundances in respective
WT glycogen (*P < 0.05, **P < 0.01, ***P < 0.001; Appendix Table S4).
ª 2017 The Authors EMBO Molecular Medicine Vol 9 | No 7 | 2017
Felix Nitschke et al Abnormal glycogen chain length underlies LD EMBO Molecular Medicine
911
Published online: May 23, 2017 
2015; Contreras et al, 2016; Turnbull et al, 2016). In that publica-
tion, however, several important issues had remained unaddressed.
First, possibly the rescue could be effected by the mere overabun-
dance of (inactive) laforin solubilizing the malstructured (long-
chained) glycogen. Second, the rescue could have been due to the
persistence of residual laforin phosphatase activity, either in the
mice considered full laforin knockouts or in the overexpressed
laforin transgene. Based on recently published structural informa-
tion, laforin might possess a heretofore unrecognized second phos-
phatase site that would have been unaffected by the C265S
transgene mutation (Sankhala et al, 2015). We now rule all these
possibilities out. We show that the same inactive laforin overexpres-
sion does not correct the abnormal glycogen accumulation/LBs in
malin-deficient LD and that the correction in laforin-deficient LD
includes normalization of both glycogen chain distribution and
content, unequivocally indicating that the rescue has a metabolic,
glycogen-related basis. We also show that the rescue occurs with no
reduction in glycogen hyperphosphorylation, ruling out that it is
due to any residual laforin phosphatase activity.
Our results show that glycogen hyperphosphorylation does not corre-
late with LB formation. Hyperphosphorylation is shared by Epm2a/,
Epm2b/, Epm2a/.C265SLaf (rescued), Epm2a/.C266SLaf (res-
cued), and Epm2b/.C266SLaf (not rescued) genotypes and can there-
fore not be the cause of LB formation (Fig 7). The glycogen chain
length abnormality, on the other hand, is shared by the Epm2a/,
Epm2b/, and Epm2b/.C266SLaf (not rescued) mice, strictly
correlating with LB formation and glycogen accumulation (Fig 7).
This together with the well-established facts that longer glucan
chains are less water soluble as they form stable double helices and
that isolated LBs consist of poorly branched glucans (Sakai et al,
1970; Gidley & Bulpin, 1987; Hejazi et al, 2009) strongly supports
the notion that chain length abnormality is the actual cause of glyco-
gen precipitation and, over time, accumulation into LBs.
Phosphatase-inactive laforin rescues glycogen precipitation and
accumulation in the Epm2a/.C265SLaf and Epm2a/.C266SLaf
but not Epm2b/.C266SLaf mice. As the relevant difference
between these genotypes is that the latter lacks malin and has an
abnormal glycogen chain length pattern, it is safe to conclude that
laforin confers its effect strictly together with malin. Previous
publications afford insights into the mechanisms through which
malin could prevent the generation of glycogen molecules with
abnormally long chains. As mentioned, in cell culture experiments
malin has consistently been shown to ubiquitinate, in a laforin-
dependent fashion, GS and proteins involved in GS activation
(PTG/R5 and R6), targeting them to proteasomal or autophagic
degradation (Vilchez et al, 2007; Worby et al, 2008; Rubio-Villena
et al, 2013). On the surface, this mechanism conflicted with
the lack of overall elevated GS activity in LD mouse tissues
(Tagliabracci et al, 2008; DePaoli-Roach et al, 2010). These results
can, however, be reconciled if the action of the laforin–malin
complex is restricted to a small subset of glycogen molecules.
Glycogen is heterogeneous, in both size (Wanson & Drochmans,
1968; Marchand et al, 2002; Nitschke et al, 2013) and chain length
distribution (i.e., some glycogen molecules contain longer chains)
(Palmer et al, 1983; Nitschke et al, 2013). The laforin–malin system
would be required only for those molecules/molecule regions in
which glucan chains approach thresholds to insolubility. Consistent
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with this is the observation that laforin’s carbohydrate binding
domain has greater affinity to longer rather than shorter glucan
chains (Chan et al, 2004; Lohi et al, 2005; Dias et al, 2016). A
reduced chain elongation would prevent progression towards precip-
itation, and since the activity would be localized, its absence would
not result in detectably increased global GS activity.
Aguado et al (2010) reported that their murine Epm2a/ LD
model has an impairment of autophagy, and Criado et al (2012) that
this impairment presents prior to the appearance of detectable
glycogen accumulations/LBs. Gayarre et al (2014) showed that
phosphatase-inactive laforin restores autophagy as it rescues LD and
proposed that laforin–malin prevents LB formation via autophagy.
In contrast and in line with recent publications (Irimia et al, 2015;
Wang et al, 2016), we do not detect presence of an autophagic
impairment in the Epm2a/ and Epm2b/ animals used to
prepare the new transgenic mice generated here and can, therefore,
not confirm autophagy correction by laforin–malin. Additionally,
other recent work showed that disturbances of autophagy markers
present in LD are correctable by genetic reduction of GS activity
(Duran et al, 2014), suggesting that the autophagy impairment may
be secondary to the glycogenosis. Notwithstanding, it is entirely
possible that laforin–malin acts locally to eliminate, through
autophagy, individual glycogen molecules that are “at risk” of
precipitation. In fact, malin was recently shown to be able to medi-
ate K63-linked ubiquitination, which can result in p62-mediated
substrate targeting to autophagy (Sanchez-Martin et al, 2015). Since
laforin preferentially binds glycogen molecules with longer chains
(see above), it is conceivable that malin could ubiquitinate laforin
through K63 ubiquitination and target laforin-bound “at-risk” glyco-
gen molecules to autophagy.
As our results show that phosphorylation is not causative of
glycogen precipitation and accumulation, what, if any, are the func-
tions of glycogen phosphates? In starch metabolism, one established
function of monophosphate esters of amylopectin is, through their
high charges and hydrophilia, to separate amylopectin chains from
each other, rendering them fully hydrated, and thus accessible to
degrading enzymes (Edner et al, 2007; Hejazi et al, 2008; Ko¨tting
et al, 2009; Zeeman et al, 2010). As glycogen and amylopectin have
a shared chemical basis (both consist of branched alpha-glucan
chains), effects of covalent modifications, such as phosphorylation,
are expected to be similar. Phosphorylation should therefore
enhance glycogen solubility and may represent a third mechanism
to protect against precipitation of long-chained “at-risk” molecules.
It is well established that neither starch-degrading exo-amylases nor
glycogen phosphorylase can proceed beyond a phosphorylated
glucosyl residue (Lomako et al, 1994; Ko¨tting et al, 2009; Cenci
et al, 2014; Emanuelle et al, 2016). Laforin’s phosphatase role may
be, similar to starch phosphatases (Gentry et al, 2007; Ko¨tting et al,
2009), to remove the phosphates to allow reshortening of chains in
“at-risk” molecules and during glycogen digestion. Consistent with
this is the recent demonstration that glycogen dephosphorylation by
laforin occurs principally during glycogen degradation (Irimia et al,
2015). In the absence of laforin’s phosphatase activity, cycles of
partial glycogen digestion and resynthesis would lead to the time-
dependent phosphate accumulation that characterizes LD glycogen.
In summary, our results combine with recent work (Gayarre
et al, 2014) to suggest that laforin’s principle LD relevant function is
mediated through malin and directed to preventing glycogen
molecules with hyperextended chains. In the absence of either
protein, some glycogen molecules at a time precipitate and gradu-
ally over time aggregate and amass into LBs, which, reaching a
certain threshold profusion (at ~14 years of age in humans), initiate,
and then drive the progressive myoclonus epilepsy.
Materials and Methods
Mouse lines, tissue collection, and histological stain for LBs
Tissues from Epm2a/.C265SLaf mice and their controls (see
Results) were the same as utilized in Gayarre et al (2014; C57BL/
6J). These mice were 9–12 months old and of both sexes. Epm2a/.
C266SLaf and Epm2b/.C266SLaf mice and controls (see Results)
were obtained following the crossing of both Epm2a/ (Ganesh
et al, 2002; C57BL/6J) and Epm2b/ (Turnbull et al, 2010; C57BL/
6J) mice with the C266SLaf mice described previously (Chan et al,
2004; 129SvJ). Mice were housed with environmental enrichment in
ventilated cages at 20–22°C, fed a high-quality, commercially avail-
able diet, water being automatically delivered. Brains of male and
female mice were harvested after cervical dislocation of at least six
9- to 12-month-old mice from each genotype, split along the sagittal
plane, one hemisphere immediately frozen in liquid nitrogen, the
other fixed in 10% [w/v] formalin. The latter was embedded in
paraffin, sectioned and stained using the periodic acid–Schiff dias-
tase method (PASD; Chan et al, 2004). All animal procedures were
approved by The Centre for Phenogenomics Animal Care Committee
and are in compliance with the CCAC Guidelines and the OMAFRA
Animals for Research Act.
Glycogen determination
Glycogen content was determined essentially as described previ-
ously (Suzuki et al, 2001). Briefly, frozen tissue was ground in liquid
nitrogen, boiled in 30% [w/v] KOH, and precipitated thrice in 67%
[v/v] ethanol and 15 mM LiCl (at least 1 h at 30°C). After redis-
solving in water, aliquots were digested with amyloglucosidase
(Megazyme) in 80 mM sodium acetate buffer pH 4.5. Liberated
glucose was determined enzymatically (Lowry & Passonneau, 1972).
Glycogen purification from muscle for phosphate determination
Quantification of total glycogen-bound phosphate requires high
glycogen purity, because its relative amounts are very low and non-
glycogen derived phosphoesters, for example, in nucleic acids, can
severely affect the determination. Extracted muscle glycogen was
thus further purified as previously published (Tagliabracci et al,
2007). Subsequently, glycogen was repeatedly precipitated in 67%
ethanol and 15 mM LiCl (at least 1 h at 30°C) until the absence of
nucleic acids could be confirmed by UV–vis spectra of glycogen
solutions at concentrations of ~100 mM glucose equivalents.
Total glycogen phosphate quantification in muscle glycogen
Total glycogen-bound phosphate was quantified as orthophosphate
following enzymatic hydrolysis of all phospho-monoesters. To facili-
tate complete orthophosphate release, highly purified muscle
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glycogen was incubated with phosphatase together with two glyco-
gen hydrolysing enzymes. In a final volume of 65 ll, the reaction
mixture contained 100 or 200 lg glycogen, 2.5 U Antarctic phos-
phatase (NEB), 0.1 U a-amylase (Roche), 2 U amyloglucosidase
(Megazyme), 50 mM bis–Tris–propane pH 6.0, 1 mM MgCl2, and
0.1 mM ZnCl2. Following overnight incubation at 37°C, 40 ll of this
reaction mixture, and orthophosphate standards for calibration, was
used to quantify ortho-phosphate enzymatically as described previ-
ously (Nelson & Kaufman, 1987). Following the addition of equal
volume of a buffer pH 7 (100 mM imidazole–HCl, 10 mM MgCl2,
5 mM EDTA), in a total volume of 80 ll, orthophosphate, via G1P,
is converted to G6P using 0.02 mg rabbit phosphorylase a (Sigma),
67 lg purified rabbit muscle glycogen, and 1 U phosphoglucomu-
tase (Sigma). Fluorescence (ex340/em470) was read until stable,
first, after the addition of 150 ll 20 mM Tris pH 8, 60 lM NADP,
and again, after the addition of 0.4 U G6PDH (Roche) in 5 ll
20 mM Tris pH 8. The G6PDH-dependent increase in fluorescence
was used to calculate the orthophosphate amounts in samples origi-
nally containing 100 or 200 lg glycogen. Glucose-based phosphate
amounts of the latter two measurements for each sample were aver-
aged and deviated < 5% indicating that the enzymatic orthophos-
phate release was complete.
Glycogen purification from brain
Initial attempts to quantify C6 phosphate in brain glycogen were
unsuccessful when following an isolation procedure similar to that
used for muscle glycogen. Unexpected high values of apparent
glucosyl C6 phosphate residues in hydrolysates of brain glycogen
indicated the presence of a contaminant that greatly affected the
measurements. The ratio of contaminant to glycogen was much
higher in samples with low glycogen content, such as WT, suggest-
ing that the contaminant is unrelated to glycogen but derives from
other constituents of brain (whose glycogen content appears to be
low as compared to other organs). Further experiments confirmed
that the contaminant is very likely glucose 6-phosphate released
during acid hydrolysis from a glycan-containing compound other
than glycogen. This contamination is relevant only for tissues with
low glycogen content, such as brain. Systematic experiments were
conducted to remove the contaminant while retaining the little
glycogen using spare WT mouse brains. After the extraction of
glycogen from 100 to 400 mg ground frozen brain tissue in 30%
KOH and three consecutive precipitations in 67% ethanol and
15 mM LiCl (see extraction of muscle glycogen for glycogen deter-
mination), the following procedure was established for all brain
glycogen samples analysed in this study. The resulting pellet,
containing glycogen, most likely proteins, and the contaminant, was
resuspended in 100 ll water and subsequently extracted with 900 ll
2:1 methanol:chloroform [v/v] by vigorous mixing, incubation for
25 min at room temperature (RT) on a rotator, and 10 min at 85°C.
After cooling to RT, the suspension was centrifuged for 20 min at
20°C and 16,000 × g, the supernatant discarded and the pellet dried
briefly at 85°C. The extraction procedure was repeated twice,
followed by resuspending the dry pellet in 300 ll water. After
20-min incubation at 95°C with intermittent agitation, the solubi-
lized glycogen was recovered in the supernatant (S1) obtained by
centrifugation at RT (16,000 × g for 20 min). The pellet was
extracted with 100 ll 0.5 M KOH at 95°C for 45 min with
intermittent agitation. Subsequently, the extract, cooled to RT, was
centrifuged (20 min, RT, 16,000 × g), and the resultant supernatant
(S2) was combined with the solubilized glycogen (S1). The
combined supernatants (S1 + S2) were subjected to several rounds
of repeated ethanol precipitation (1,400 ll 67% ethanol, 15 mM
LiCl, 70 min at 30°C), 20 min centrifugation at 4°C and
16,000 × g, carefully discarding the supernatant, and resolubiliza-
tion of the pellet in water followed by 10-min heat treatment (95°C,
intermittent agitation). The ethanolic supernatant harbours the
contaminant, the amount of which tends to be smaller with each
round of precipitation. Glycogen pellets were considered to be
contaminant free when the apparent G6P amount in the last ethano-
lic supernatant was below the detection limit. Using the enzymatic
cycling method, the contaminant (apparent G6P) was quantified
after drying the ethanolic supernatants (SpeedVac), dissolving the
dry contaminant pellets in water, and subsequent acid hydrolysis
(see below). Glycogen concentration was determined after dissolv-
ing the purified glycogen pellet as described above. As the number
of sequential precipitations was adjusted to the persistence of the
contaminant in the ethanolic supernatant, glycogen recovery varied
but in most cases was between 50 and 80%.
Glycogen carbon C6 phosphate determination
Aliquots of purified muscle or brain glycogen preparations (see
above) were subjected to acid hydrolysis (3 h, 95°C, 0.7 M HCl)
and subsequently neutralized using 5 M KOH. G6P was determined
alongside G6P standards using the enzymatic cycling assay previ-
ously described (Nitschke et al, 2013). G6P amounts were based on
glucose amounts that were liberated during acid hydrolysis and
determined enzymatically (Lowry & Passonneau, 1972).
Determination of glycogen chain length distributions
Purified muscle or brain glycogen (10–20 lg dry weight) was
completely debranched by overnight incubation with 200 U isoamy-
lase (Sigma) in 110 ll 10 mM sodium acetate at pH 5 and 37°C.
Following heat inactivation (10 min at 95°C) and centrifugation
(10 min at 20,000 × g), 90 ll of the supernatant was applied to
high-performance anion exchange chromatography with pulsed
amperometric detection (HPAEC-PAD; ThermoFisher, ICS5000).
Separation of the oligoglucan chains was achieved on a CarboPac
PA100 column and guard combination (ThermoFisher) at a constant
flow rate of 1 ml/min with an elution profile of the two eluents A
(150 mM NaOH) and B (150 mM NaOH, 500 mM sodium acetate)
as follows: injection after 15 min 95% [v/v] A, 5% [v/v] B equili-
bration; 5 min 95% A, 5% B; 9 min linear gradient to 70% A, 30%
B; 9 min linear gradient to 55% A, 45% B; 37 min linear gradient to
33% A, 67% B; 10 min 100% B. Chromatograms were analysed
with Dionex Chromeleon software (version 7.2). For each chain
length (degree of polymerization), relative peak areas were deter-
mined, which were then averaged among at least five biological
replicates allowing the calculation of standard deviations (SD). Note
that purified glycogen from all available brain samples of the geno-
type Epm2a/.Laf was pooled to obtain sufficiently large amounts
of glycogen for the chain length distribution analysis. SD at each
chain length as a measure of biological variance for this genotype
was estimated by multiplying the average SD of the other genotypes
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(WT, Epm2a/, Epm2a/.C265SLaf) by two. As variances in rela-
tive peak areas between those genotypes are mostly equal, the esti-
mated biological variance should include 95% of samples of the
Epm2a/.Laf genotype.
Analysis of autophagy markers
For the detection of LC3 in brain tissue, a membrane fraction
enriched in autophagosomes was prepared as described previously
(Chu et al, 2009), and for p62 after extracting soluble protein as in
Wang et al (2007); 15 lg total protein was separated on 14% SDS–
PAGE using a Laemmli buffer system. Proteins of interest were
detected after transfer to PVDF membranes using primary antibodies
NB100-2220 (LC3, Novus Biologicals), P0067 (p62, Sigma),
sc-25778, and sc-11397 (GAPDH and calnexin, respectively, Santa
Cruz), all at a 1:1,000 dilution.
Statistical analyses
Except where stated, all biochemical analyses were conducted in at
least five biological replicates. Standard deviations (SD) or standard
error of mean (SEM) was calculated as indicated. Averages of multi-
ple groups of biological replicates were compared using one-way
analysis of variance (ANOVA) followed by post hoc analysis using
homoscedastic Student’s t- or heteroscedastic Welch’s tests, both
unpaired, two-tailed, and with Holm–Bonferroni correction. The
adequate post hoc test was selected based on equal or unequal vari-
ances of groups tested with F-tests. Significance levels are indicated
by asterisks (*P < 0.05, **P < 0.01, ***P < 0.001). For glycogen
chain length distribution analyses, significance between genotypes
was tested for each individual degree of polymerization.
Expanded View for this article is available online.
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